GeneDx (NASDAQ:WGS) Shares Down 7.4% - Here's What Happened

GeneDx logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • GeneDx shares fell 7.4% to $47.22, with trading volume down 88% from its average session volume.
  • The company’s latest quarterly results beat estimates: earnings were $0.28 per share versus $0.07 expected, while revenue of $123.1 million was slightly above consensus.
  • Analysts maintain a “Moderate Buy” consensus rating and an average $90.14 price target; BTIG lowered its target to $85 but kept its Buy rating.
  • MarketBeat previews top five stocks to own in December.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) shares dropped 7.4% on Tuesday. The company traded as low as $47.59 and last traded at $47.22. Approximately 116,062 shares changed hands during trading, a decline of 88% from the average session volume of 936,615 shares. The stock had previously closed at $51.02.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on WGS. BTIG Research reissued a "buy" rating and issued a $85.00 price target (down from $90.00) on shares of GeneDx in a research note on Tuesday, November 10th. Canaccord Genuity Group increased their price objective on shares of GeneDx from $75.00 to $90.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Guggenheim lifted their target price on shares of GeneDx from $74.00 to $83.00 and gave the company a "buy" rating in a report on Thursday, October 1st. Wall Street Zen raised GeneDx from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of GeneDx in a research note on Monday, November 2nd. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $90.14.

Read Our Latest Report on GeneDx

GeneDx Price Performance

The company has a market capitalization of $1.35 billion, a PE ratio of -11.99 and a beta of 2.00. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.16 and a quick ratio of 3.06. The stock's 50 day simple moving average is $73.13 and its 200-day simple moving average is $69.98.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Monday, November 9th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.21. The firm had revenue of $123.10 million for the quarter, compared to the consensus estimate of $122.93 million. GeneDx had a negative net margin of 24.10% and a positive return on equity of 1.98%. During the same period in the prior year, the firm earned ($0.27) EPS. As a group, equities analysts forecast that GeneDx Holdings Corp. will post -0.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Katherine Stueland sold 10,501 shares of the business's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the completion of the transaction, the chief executive officer directly owned 115,476 shares of the company's stock, valued at $11,271,612.36. The trade was a 8.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of the company's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total value of $363,890.08. Following the sale, the chief financial officer owned 44,945 shares in the company, valued at approximately $4,387,081.45. This trade represents a 7.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 19,206 shares of company stock worth $1,808,056 in the last ninety days. Corporate insiders own 25.17% of the company's stock.

Hedge Funds Weigh In On GeneDx

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Fifth Third Bancorp acquired a new stake in GeneDx in the first quarter valued at approximately $31,000. Nykredit A S purchased a new stake in shares of GeneDx in the 2nd quarter valued at approximately $38,000. Sterling Capital Management LLC increased its position in shares of GeneDx by 851.4% in the 3rd quarter. Sterling Capital Management LLC now owns 666 shares of the company's stock valued at $48,000 after purchasing an additional 596 shares during the last quarter. Calamos Advisors LLC acquired a new stake in shares of GeneDx in the 3rd quarter valued at $225,000. Finally, Cetera Investment Advisers raised its holdings in shares of GeneDx by 16.6% in the 1st quarter. Cetera Investment Advisers now owns 3,616 shares of the company's stock valued at $232,000 after purchasing an additional 516 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

About GeneDx

(Get Free Report)

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company's testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GeneDx Right Now?

Before you consider GeneDx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.

While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines